Loading...

VAXART INC Investments/Divestments 8-K Filing

VXRT

VAXART INC

()

2024 8-K

Show Summary

Summary

Special Meeting Delayed

Nasdaq Listing Continuation

Fireside Chat Report

Management Announcement

Financial Results Announcement

Clinical Trials

Voluntary Delisting

Forced Delisting

Clinical Trials

Adjournment of Meeting

Reverse Stock Split

Product Expansion

New Product Launches

Financial Statements

Reverse Stock Split

Reverse Stock Split

Clinical Trials

Financial Results

Vaccine Trial Announcement

Funding Increase

Clinical Trial Update

Nasdaq Compliance Notice

Funding Increase

Vaccine Trial Update

Q3 Financial Results

Sales Agreement Termination

Funding Increase

Earnings Reports

Amendment to Voting Results

Underwriting Agreement

BARDA Funding Agreement

Amendment and Restatement o...

Earnings Reports

Clinical Trial Completion

Financial Results Announcement

Appointment of CEO

Management Changes

Compliance regained with Na...

Amendment - Separation Agre...

Delisting Notice

Securities Purchase Agreeme...

Contract Award and CEO Resi...

Financial Results Announcement

Disclosure of Say-on-Pay Vo...

Bylaws Amendment

Earnings Reports

Delisting Notice

Annual Meeting of Stockholders

Underwriting Agreement

Press Release Update

Compliance regained with Na...

Earnings Reports

Earnings Reports

External Links:

Vaxart, Inc. has been awarded a contract by the U.S. Government for a Phase 2b clinical trial of their XBB vaccine candidate, with a total contract value of $9,271,193.00. The CEO, Andrei Floroiu, has resigned and Dr. Michael J. Finney has been appointed as Interim CEO.

AI Assistant

VAXART INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.